Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387. Speaking at a Canaccord Genuity event, Chief Operating Officer Ross Moat said Kiniksa reported approximately $243 million in net revenue during the second quarter, representing $29 million […]